Gilead Sciences Work in process decreased by 2.3% to $1.28B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 18.6%, from $1.08B to $1.28B. Over 5 years (FY 2020 to FY 2025), Work in process shows an upward trend with a 6.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase may indicate production bottlenecks or scaling efforts, while a decrease suggests efficient throughput or reduced manufacturing activity.
Represents the value of goods that have entered the production process but are not yet finished. For a manufacturer like...
Peers in medical device manufacturing typically maintain lean WIP levels to optimize cash conversion cycles.
inv_work_in_progress| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $924.00M | $727.00M | $590.00M | $540.00M | $484.00M | $430.00M | $577.00M | $570.00M | $622.00M | $614.00M | $847.00M | $778.00M | $803.00M | $684.00M | $847.00M | $1.08B | $1.04B | $1.34B | $1.31B | $1.28B |
| QoQ Change | — | -21.3% | -18.8% | -8.5% | -10.4% | -11.2% | +34.2% | -1.2% | +9.1% | -1.3% | +37.9% | -8.1% | +3.2% | -14.8% | +23.8% | +27.0% | -3.4% | +29.1% | -2.6% | -2.3% |
| YoY Change | — | — | — | — | -47.6% | -40.9% | -2.2% | +5.6% | +28.5% | +42.8% | +46.8% | +36.5% | +29.1% | +11.4% | +0.0% | +38.3% | +29.4% | +96.1% | +54.2% | +18.6% |
| % of Inventories | 76.0% | 64.9% | 52.9% | 45.2% | 44.2% | 37.8% | 43.9% | 39.7% | 40.2% | 39.9% | 53.7% | 51.5% | 59.0% | 43.7% | 45.1% | 53.3% | 49.8% | 51.5% | 50.3% | 52.6% |
| Share Change | — | -11.1pp | -12.0pp | -7.6pp | -1.0pp | -6.5pp | +6.2pp | -4.2pp | +0.5pp | -0.3pp | +13.8pp | -2.2pp | +7.4pp | -15.3pp | +1.4pp | +8.2pp | -3.5pp | +1.8pp | -1.2pp | +2.3pp |